Screener
Madrigal Pharmaceuticals, Inc. MDGL Business Segments — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Facility related and other internal expenses(1) | (1,486) | (1,656) | (2,669) | (2,781) |
| Selling, general and administrative: | ||||
| Compensation and benefit-related expenses | (80,321) | (52,504) | (163,926) | (100,865) |
| Stock-based compensation | (28,382) | (19,805) | (54,439) | (35,521) |
| Professional fees and other external expenses | (148,996) | (109,841) | (280,248) | (197,855) |
| Facility related and other internal expenses(1) | (31,676) | (14,708) | (59,283) | (30,493) |
| Other segment (expense) income(2) | (1,631) | 4,921 | (3,299) | 10,994 |
| Net loss | $(57,939) | $(42,281) | $(152,330) | $(115,519) |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s business segments — stock-based comp?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported business segments — stock-based comp of $28.38M in Q2 2026.
- What does business segments — stock-based comp mean?
- This represents the non-cash expense recognized for equity-based awards granted to employees and directors. It is a key metric for understanding the total cost of talent acquisition and retention beyond cash salaries.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s business segments — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude